Androgen receptor polyQ alleles and COVID‐19 severity in men : A replication study
Abstract Background Ample evidence indicates a sex‐related difference in severity of COVID‐19, with less favorable outcomes observed in men. Genetic factors have been proposed as candidates to explain this difference. The polyglutamine (polyQ) polymorphism in the androgen receptor gene has been recently described as a genetic biomarker of COVID‐19 severity. Objective To test the association between the androgen receptor polyQ polymorphism and COVID‐19 severity in a large cohort of COVID‐19 male patients. Materials and methods This study included 1136 male patients infected with SARS‐CoV‐2 as confirmed by positive PCR. Patients were retrospectively and prospectively enrolled from March to November 2020. Patients were classified according to their severity into three categories: oligosymptomatic, hospitalized and severe patients requiring ventilatory support. The number of CAG repeats (polyQ polymorphism) at the androgen receptor was obtained by PCR and patients were classified as either short (<23 repeats) or long (≥23 repeats) allele carriers. The association between polyQ alleles (short or long) and COVID‐19 severity was assessed by Chi‐squared (Chi2) and logistic regression analysis. Results The mean number of polyQ CAG repeats was 22 (±3). Patients were classified as oligosymptomatic (15.5%), hospitalized (63.2%), and severe patients (21.3%) requiring substantial respiratory support. PolyQ alleles distribution did not show significant differences between severity classes in our cohort (Chi2 test p > 0.05). Similar results were observed after adjusting by known risk factors such as age, comorbidities, and ethnicity (multivariate logistic regression analysis). Discussion Androgen sensitivity may be a critical factor in COVID‐19 disease severity. However, we did not find an association between the polyQ polymorphism and the COVID‐19 severity. Additional studies are needed to clarify the mechanism underlying the association between androgens and COVID‐19 outcome. Conclusions The results obtained in our study do not support the role of this polymorphism as biomarker of COVID‐19 severity..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Andrology - 11(2023), 1, Seite 24-31 |
| Beteiligte Personen: |
López‐Rodríguez, Rosario [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2023 American Society of Andrology and European Academy of Andrology. |
|---|
| Umfang: |
8 |
|---|
| doi: |
10.1111/andr.13339 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY001730282 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY001730282 | ||
| 003 | DE-627 | ||
| 005 | 20230307110143.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230210s2023 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/andr.13339 |2 doi | |
| 028 | 5 | 2 | |a ANDR_ANDR13339.xml |
| 035 | |a (DE-627)WLY001730282 | ||
| 035 | |a (WILEY)ANDR13339 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.88 |2 bkl | ||
| 100 | 1 | |a López‐Rodríguez, Rosario |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Androgen receptor polyQ alleles and COVID‐19 severity in men |b A replication study |
| 264 | 1 | |c 2023 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2023 American Society of Andrology and European Academy of Andrology. | ||
| 520 | |a Abstract Background Ample evidence indicates a sex‐related difference in severity of COVID‐19, with less favorable outcomes observed in men. Genetic factors have been proposed as candidates to explain this difference. The polyglutamine (polyQ) polymorphism in the androgen receptor gene has been recently described as a genetic biomarker of COVID‐19 severity. Objective To test the association between the androgen receptor polyQ polymorphism and COVID‐19 severity in a large cohort of COVID‐19 male patients. Materials and methods This study included 1136 male patients infected with SARS‐CoV‐2 as confirmed by positive PCR. Patients were retrospectively and prospectively enrolled from March to November 2020. Patients were classified according to their severity into three categories: oligosymptomatic, hospitalized and severe patients requiring ventilatory support. The number of CAG repeats (polyQ polymorphism) at the androgen receptor was obtained by PCR and patients were classified as either short (<23 repeats) or long (≥23 repeats) allele carriers. The association between polyQ alleles (short or long) and COVID‐19 severity was assessed by Chi‐squared (Chi2) and logistic regression analysis. Results The mean number of polyQ CAG repeats was 22 (±3). Patients were classified as oligosymptomatic (15.5%), hospitalized (63.2%), and severe patients (21.3%) requiring substantial respiratory support. PolyQ alleles distribution did not show significant differences between severity classes in our cohort (Chi2 test p > 0.05). Similar results were observed after adjusting by known risk factors such as age, comorbidities, and ethnicity (multivariate logistic regression analysis). Discussion Androgen sensitivity may be a critical factor in COVID‐19 disease severity. However, we did not find an association between the polyQ polymorphism and the COVID‐19 severity. Additional studies are needed to clarify the mechanism underlying the association between androgens and COVID‐19 outcome. Conclusions The results obtained in our study do not support the role of this polymorphism as biomarker of COVID‐19 severity. | ||
| 700 | 1 | |a Ruiz‐Hornillos, Javier |4 aut | |
| 700 | 1 | |a Cortón, Marta |4 aut | |
| 700 | 1 | |a Almoguera, Berta |4 aut | |
| 700 | 1 | |a Minguez, Pablo |4 aut | |
| 700 | 1 | |a Pérez‐Tomás, María Elena |4 aut | |
| 700 | 1 | |a Barreda‐Sánchez, María |4 aut | |
| 700 | 1 | |a Mancebo, Esther |4 aut | |
| 700 | 1 | |a Ondo, Lorena |4 aut | |
| 700 | 1 | |a Martínez‐Ramas, Andrea |4 aut | |
| 700 | 1 | |a Fernández‐Caballero, Lidia |4 aut | |
| 700 | 1 | |a Taracido‐Fernández, Juan Carlos |4 aut | |
| 700 | 1 | |a Herrero‐González, Antonio |4 aut | |
| 700 | 1 | |a Mahillo, Ignacio |4 aut | |
| 700 | 1 | |a Paz‐Artal, Estela |4 aut | |
| 700 | 1 | |a Guillén‐Navarro, Encarna |4 aut | |
| 700 | 1 | |a Ayuso, Carmen |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Andrology |g 11(2023), 1, Seite 24-31 |w (DE-627)WLY001723847 |x 20472927 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2023 |g number:1 |g pages:24-31 |g extent:8 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 936 | b | k | |a 44.88 |q ASE |
| 951 | |a AR | ||
| 952 | |d 11 |j 2023 |e 1 |h 24-31 |g 8 | ||